Last reviewed · How we verify
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
To characterize safety associated with the use of Kyprolis under the locally approved label.
Details
| Lead sponsor | Amgen |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 101 |
| Start date | Mon Sep 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jun 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Relapsed Refractory Multiple Myeloma
Interventions
- Drug: Carfilzomib + Dexamethasone
- Drug: Carfilzomib + Lenalidomide + Dexamethasone
Countries
India